Anika Therapeutics, Inc.
HealthcareNASDAQ:ANIK · NASDAQ Global Select
+$0.00 today
Vol 0.05M · Avg 0.11M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$116.3M of revenue converted into -$11.1M of net income for the selected period. Gross margin is 58.4% and net margin is -9.6%, showing how much revenue survives after costs and taxes. EPS is $-0.79, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $112.8M -5.9% | $119.9M -0.7% | $120.8M +6.1% | $113.8M -23.0% | $147.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $49.0M +11.6% | $43.9M +14.8% | $38.3M -5.8% | $40.6M -37.4% | $64.9M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $63.8M -16.0% | $76.0M -7.9% | $82.5M +12.7% | $73.2M -11.7% | $82.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 56.6% -6.8pp | 63.4% -4.9pp | 68.3% +4.0pp | 64.3% +8.2pp | 56.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $25.8M +0.9% | $25.5M +17.4% | $21.8M +18.8% | $18.3M -33.0% | $27.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $49.1M -11.6% | $55.6M -7.3% | $59.9M +17.0% | $51.2M -30.9% | $74.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $74.9M -7.7% | $81.1M -0.7% | $81.7M +17.5% | $69.5M -13.4% | $80.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.7M -29.5% | $8.1M -42.9% | $14.2M -1.9% | $14.5M +1.2% | $14.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$3.6M -166.8% | $5.4M -69.2% | $17.4M -7.6% | $18.8M +551.9% | -$4.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -3.2% -7.6pp | 4.5% -9.9pp | 14.4% -2.1pp | 16.5% +19.3pp | -2.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$11.1M -116.6% | -$5.1M -704.4% | $844.0K -77.0% | $3.7M +40.3% | $2.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -9.8% -5.5pp | -4.3% -5.0pp | 0.7% -2.5pp | 3.2% +1.5pp | 1.8% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | — | $2.3M +253.5% | $654.0K | — | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | — | $0 | $0 | — | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.7M -25.4% | $2.3M +1.1% | $2.3M +253.5% | $654.0K +447.9% | -$188.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$9.3M -236.7% | -$2.8M -187.6% | $3.2M -27.0% | $4.3M +78.2% | $2.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -8.2% -5.9pp | -2.3% -4.9pp | 2.6% -1.2pp | 3.8% +2.2pp | 1.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $672.0K -88.9% | $6.1M -8.1% | $6.6M +210.5% | $2.1M +224.4% | -$1.7M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$10.9M +80.7% | -$56.4M +31.8% | -$82.7M -456.3% | -$14.9M -459.4% | $4.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -9.6% +37.4pp | -47.0% +21.4pp | -68.4% -55.4pp | -13.1% -15.9pp | 2.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +80.2% | -$4 +32.1% | -$6 -452.9% | -$1 -451.7% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +80.2% | -$4 +32.1% | -$6 -452.9% | -$1 -464.3% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $14.3M -2.6% | $14.7M +0.4% | $14.7M +0.7% | $14.6M +1.1% | $14.4M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $14.3M -2.6% | $14.7M +0.4% | $14.7M +0.7% | $14.6M -0.5% | $14.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Anteris Technologies Global Corp.
NASDAQ:AVR
$336.61M
Apyx Medical Corporation
NASDAQ:APYX
$196.39M
Quipt Home Medical Corp.
QIPT
$162.30M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Lucid Diagnostics Inc.
NASDAQ:LUCD
$98.28M
Owlet, Inc.
NYSE:OWLT
$84.14M
Anixa Biosciences, Inc.
NASDAQ:ANIX
$84.04M
Rapid Micro Biosystems, Inc.
NASDAQ:RPID
$79.77M
LENSAR, Inc.
NASDAQ:LNSR
$70.45M
Accuray Incorporated
ARAY
$40.60M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ANIK generate?
Anika Therapeutics, Inc. (ANIK) reported $112.82M of revenue in fiscal 2025.
Is ANIK profitable?
Anika Therapeutics, Inc. (ANIK) reported -$10,880,000.00 of net income, with a net margin of -9.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.